Summary of HTLV-I/II Antibody Reactivity in CD3-LDGL Patients*
| . | . | HTLV Blot 2.3 . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | . | |||
| SERA . | env . | gag . | p21e . | Epitope . | Mapping . | |||
| . | p21e . | gp46-I . | gp46-II . | p19 . | p24 . | GD21-1 . | GD21-2 . | BA-21 . |
| 1 | — | — | — | — | — | — | — | — |
| 2 | + | — | — | — | — | — | — | + |
| 3 | ++ | — | — | — | + | — | — | ++ |
| 4 | ++ | — | — | — | — | — | — | ++ |
| 5 | ± | — | — | — | — | — | — | + |
| 6 | + | — | — | + | + | — | — | + |
| 7 | — | — | — | — | — | — | — | — |
| 8 | + | — | — | — | — | — | — | + |
| 9 | + | — | + | ± | — | — | — | — |
| 10 | ++ | — | — | ± | — | — | — | ++ |
| 11 | — | — | — | ± | — | — | — | — |
| 12 | ++ | — | — | — | — | — | — | ++ |
| 13 | — | — | — | — | — | — | — | — |
| 14 | + | — | — | — | — | — | — | ++ |
| 15 | + | — | — | — | — | — | — | + |
| . | . | HTLV Blot 2.3 . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | . | |||
| SERA . | env . | gag . | p21e . | Epitope . | Mapping . | |||
| . | p21e . | gp46-I . | gp46-II . | p19 . | p24 . | GD21-1 . | GD21-2 . | BA-21 . |
| 1 | — | — | — | — | — | — | — | — |
| 2 | + | — | — | — | — | — | — | + |
| 3 | ++ | — | — | — | + | — | — | ++ |
| 4 | ++ | — | — | — | — | — | — | ++ |
| 5 | ± | — | — | — | — | — | — | + |
| 6 | + | — | — | + | + | — | — | + |
| 7 | — | — | — | — | — | — | — | — |
| 8 | + | — | — | — | — | — | — | + |
| 9 | + | — | + | ± | — | — | — | — |
| 10 | ++ | — | — | ± | — | — | — | ++ |
| 11 | — | — | — | ± | — | — | — | — |
| 12 | ++ | — | — | — | — | — | — | ++ |
| 13 | — | — | — | — | — | — | — | — |
| 14 | + | — | — | — | — | — | — | ++ |
| 15 | + | — | — | — | — | — | — | + |
Intensity of antibody reactivity is indicated by the following scale: — , no reactivity; ±, weak reactivity.
+, Moderate reactivity; ++, strong reactivity.